GILD · News · 20260805N

HIV and PrEP Demand Growth

GILEAD SCIENCES, INC. · 2026-08-05 · Importance 48 · Surprise 40

Gilead’s HIV portfolio generated 12% year-over-year sales growth in the second quarter, reflecting continued strength in treatment products and rapid expansion of its PrEP business. HIV prevention medicines exceeded $1 billion in quarterly sales for the first time. Growth was driven by products including Biktarvy and Descovy, with PrEP adoption supported by expanded prevention access and outreach. The demand trend spans the broader HIV market, including prevention programs and community-based delivery in markets such as Kenya.

Key facts